Evidence map›Paper›PMID 22972448›Full record

Trial reportRetina (Philadelphia, Pa.)2013

Score Study Report 12: Development of venous collaterals in the Score Study.

David V Weinberg, Aimee E Wahle, Michael S Ip, Ingrid U Scott, Paul C VanVeldhuisen, Barbara A Blodi, SCORE Study Investigator Group

Open access · greenAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Retina (Philadelphia, Pa.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Disease-modifying effects of ranibizumab for central retinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Trial
  4. Trial
  5. The influence of different types of collateral vessels on the recurrence of macular edema in branch retinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Morphological differences between optic disc collaterals and neovascularization on optical coherence tomography angiography.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017
    Article
  15. [Retinal vein occlusion : Epidemiology, classification and clinical findings].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2015
    Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

David V WeinbergMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Aimee E Wahle
Michael S Ip
Ingrid U Scott
Paul C VanVeldhuisen
Barbara A Blodi
SCORE Study Investigator Group
Emmes (United States) · USUniversity of Wisconsin–Madison · USMedical College of Wisconsin · USPenn State Milton S. Hershey Medical Center · US

Funding

The Intravitreal Corticosteroid for Macular Edema StudyU10EY014351 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI IP, MICHAEL S · 2003 to 2008
$11.5M
SCORE2 Comparative Trial (SCT)U10EY023529 · NEI · THE EMMES COMPANY, LLC · PI VAN VELDHUISEN, PAUL C · 2013 to 2018
$6.8M
Intravitreal Corticosteroid for Macular EdemaU10EY014404 · NEI · THE EMMES COMPANY, LLC · PI VAN VELDHUISEN, PAUL C · 2003 to 2008
$3.8M
Intravitreal Corticosteroid for Macular Edema StudyU10EY014352 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI BLODI, BARBARA A · 2003 to 2008
$1.1M
NEI NIH HHS 5U10EY014351NEI NIH HHS 5U10EY014352NEI NIH HHS 5U10EY014404NEI NIH HHS U10 EY014351NEI NIH HHS U10 EY014352NEI NIH HHS U10 EY014404NEI NIH HHS U10 EY023529
6 · The paper itself

Abstract

purposeTo investigate the prevalence of venous collaterals after branch and central retinal vein occlusion, assess the association of venous collaterals with other clinical features (including visual acuity), and determine if treatment with intravitreal corticosteroids influences the development of new venous collaterals.

methodsReview of data from two multicenter randomized clinical trials in the Standard of Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study.

resultsStatistically significant associations of venous collaterals and visual acuity at baseline or at follow-up were not found. Treatment with intravitreal triamcinolone acetonide did not appear to influence the development of venous collaterals.

conclusionIn contrast to some previous reports, development of venous collaterals did not demonstrate an independent association with visual acuity in eyes with branch retinal vein occlusion or central retinal vein occlusion in the SCORE Study. Intravitreal steroid effects do not appear to influence the development of venous collaterals.

Indexed as

Collateral CirculationFemaleFluorescein AngiographyGlucocorticoidsHumansIntravitreal InjectionsMacular EdemaMaleOptic DiskRetinal VeinRetinal Vein OcclusionTomography, Optical CoherenceTriamcinolone AcetonideVisual AcuityGlucocorticoidsTriamcinolone Acetonide

Identifiers

PMID22972448
PMCPMC5668867
OpenAlexW2034294591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.